` RVNC (Revance Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

RVNC
vs
S&P 500

Over the past 12 months, RVNC has underperformed S&P 500, delivering a return of -9% compared to the S&P 500's +13% growth.

Stocks Performance
RVNC vs S&P 500

Loading
RVNC
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RVNC vs S&P 500

Loading
RVNC
S&P 500
Difference
www.alphaspread.com

Performance By Year
RVNC vs S&P 500

Loading
RVNC
S&P 500
Add Stock

Competitors Performance
Revance Therapeutics Inc vs Peers

S&P 500
RVNC
LLY
JNJ
NOVO B
ROG
Add Stock

Revance Therapeutics Inc
Glance View

Market Cap
382.9m USD
Industry
Pharmaceuticals

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 495 full-time employees. The company went IPO on 2014-02-06. The firm is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The firm is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. The company offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

RVNC Intrinsic Value
7.09 USD
Undervaluation 48%
Intrinsic Value
Price
Back to Top